Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Elekta AB ( ($SE:EKTA.B) ) is now available.
Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025. With a strong background in international leadership and innovation, Just-Bomholt is expected to drive Elekta’s growth and global expansion, enhancing its market position and delivering value to stakeholders, including shareholders, customers, and cancer patients worldwide.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care through sustainable, outcome-driven, and cost-efficient solutions. With a global team of 4,500 employees, Elekta focuses on advancing cancer treatment technology and is headquartered in Stockholm, Sweden, with offices in over 40 countries.
YTD Price Performance: -16.61%
Average Trading Volume: 1,326,919
Current Market Cap: SEK19.09B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue